Efficacy and Safety Study of Combination of Ginkgo Extract and Ginseng Extract in Children With ADHD(Attention Deficit Hyperactivity Disorder)

Inclusion Criteria:

• Mele and female subjects aged from 6 to 15

• Subjects must meet DSM-IV criteria for ADHD based-on the K-Schedule for affectivedisorder and schizophrenia(K-SADS-PL-K)interview

• Subjects signed a written consent form voluntarily

• Patient's assent to participate in the study and written informed consent form signedby one of the parents, parent surrogates or legal guardian.

• Subjects who can keep visit schedule and whose parent/parent surrogates or legalguardian can willingly complete assessments defined in the study protocol.

• Subjects/parents, parent surrogates or legal guardian who can understand theparticipation of the study and voluntarily withdraw from the study at any time.

Exclusion Criteria:

• Subjects who have difficulty swallowing tablet.

• Subjects who have known allergy to plant extracts.

• Subjects who meet DSM-IV diagnostic criteria for current major depressive disorder oranxiety disorder requiring drug therapy.

• Subjects who have any history of bipolar disorder, psychotic disorder, and substanceuse disorder, have been diagnosed with a pervasive developmental disorder, organicbrain disease and seizure disorder.

• Subjects who have significant suicidal ideation.

• Subjects with mental retardation.

• Subjects with Tourette's syndrome requiring drug therapy.

• Subjects who have been administrated Methylphenidate or Atomoxetine within recent 3months and Ginkgo extract or Ginseng extract within recent 1 month.

• Subjects who currently have a significant medical conditions(e.g. diseases ofcardiovascular, hepatic, renal, respiratory, glaucoma)

• Subjects who have abnormalities in the ECG or show clinically significantabnormalities of laboratory results including serum chemistries and hematology.

• subjects who are currently taking alpha-2 adrenergic receptor agonist, antidepressant,antipsychotic, benzodiazepines, modafinil, anticonvulsant.

• subjects who receive psychosocial treatment during the drug trial.

• Subjects who are not able to swallow the study drug.